Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension

Overview

Journal J Cardiovasc Pharmacol

Date 2016 Jan 9

PMID 26745002

Citations 12

Authors

Satoshi Akagi

Kazufumi Nakamura

Hiromi Matsubara

Megumi Kondo

Daiji Miura

Tetsuya Matoba

Kensuke Egashira

Hiroshi Ito

Affiliations

Soon will be listed here.

Abstract

Nanoparticles (NPs) have been used as novel drug delivery systems. Drug-incorporated NPs for local delivery might optimize the efficacy and minimize the side effects of drugs. Intravenous prostacyclin improves long-term survival in patients with pulmonary arterial hypertension (PAH), but it causes serious side effects such as catheter-related infections. We investigated the efficacy and safety of intratracheal administration of a prostacyclin analogue, beraprost (BPS), incorporated NPs in Sugen-hypoxia-normoxia and monocrotaline rat models of PAH and in human PAH pulmonary arterial smooth muscle cells (PASMCs). After a single administration, BPS NPs significantly decreased right ventricular pressure, right ventricular hypertrophy, and pulmonary artery muscularization in the 2 rat models. BPS NPs significantly improved the survival rate in the monocrotaline rat model. No infiltration of inflammatory cells, hemorrhage, or fibrosis was found in the liver, kidney, spleen, and heart after the administration of BPS NPs. No liver or kidney dysfunction was found in the blood examinations. BPS and BPS NPs significantly inhibited the proliferation of human PAH PASMCs after 24 hours of treatment. BPS NPs significantly continued to inhibit the proliferation of human PAH PASMCs at 24 hours after the removal of BPS NPs. BPS NPs significantly induced apoptosis in PAH PASMCs compared to that in non-PAH PASMCs. Intratracheal administration of BPS NPs ameliorates pulmonary hypertension in PAH rat models by a sustained antiproliferative effect and a proapoptotic effect on PAH PASMCs.

Citing Articles

Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment.

Park J, Choi Y, Min J, Lee J, Shim G Pharmaceutics. 2025; 17(2).

PMID: 40006591 PMC: 11859843. DOI: 10.3390/pharmaceutics17020224.

Research Progress on Using Nanoparticles to Enhance the Efficacy of Drug Therapy for Chronic Mountain Sickness.

Liang B, Zhou Y, Qin Y, Li X, Zhou S, Yuan K Pharmaceutics. 2024; 16(11).

PMID: 39598498 PMC: 11597246. DOI: 10.3390/pharmaceutics16111375.

Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.

Corboz M, Nguyen T, Stautberg A, Cipolla D, Perkins W, Chapman R J Aerosol Med Pulm Drug Deliv. 2024; 37(5):241-283.

PMID: 39388691 PMC: 11502635. DOI: 10.1089/jamp.2024.0016.

Nanotechnology Innovations in Pediatric Cardiology and Cardiovascular Medicine: A Comprehensive Review.

Moisa S, Burlacu A, Butnariu L, Vasile C, Brinza C, Spoiala E Biomedicines. 2024; 12(1).

PMID: 38255290 PMC: 10813221. DOI: 10.3390/biomedicines12010185.

Evidence for Hypoxia-Induced Shift in ATP Production from Glycolysis to Mitochondrial Respiration in Pulmonary Artery Smooth Muscle Cells in Pulmonary Arterial Hypertension.

Akagi S, Nakamura K, Kondo M, Hirohata S, Udono H, Nishida M J Clin Med. 2023; 12(15).

PMID: 37568430 PMC: 10419513. DOI: 10.3390/jcm12155028.

References

Akagi S, Matsubara H, Ogawa A, Kawai Y, Hisamatsu K, Miyaji K . Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension. Circ J. 2007; 71(4):559-64. DOI: 10.1253/circj.71.559. View

Akagi S, Nakamura K, Miura D, Saito Y, Matsubara H, Ogawa A . Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension. Int Heart J. 2015; 56(3):354-9. DOI: 10.1536/ihj.14-338. View

Olschewski H, Hoeper M, Behr J, Ewert R, Meyer A, Borst M . Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010; 104(5):731-40. DOI: 10.1016/j.rmed.2010.01.008. View

Akagi S, Nakamura K, Miyaji K, Ogawa A, Kusano K, Ito H . Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J. 2010; 74(10):2200-5. DOI: 10.1253/circj.cj-10-0190. View

Kim B, Rutka J, Chan W . Nanomedicine. N Engl J Med. 2010; 363(25):2434-43. DOI: 10.1056/NEJMra0912273. View

Chen L, Nakano K, Kimura S, Matoba T, Iwata E, Miyagawa M . Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension. 2011; 57(2):343-50. DOI: 10.1161/HYPERTENSIONAHA.110.157032. View

Akagi S, Nakamura K, Matsubara H, Kusano K, Kataoka N, Oto T . Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol. 2011; 165(3):499-505. DOI: 10.1016/j.ijcard.2011.09.004. View

Matoba T, Egashira K . Nanoparticle-mediated drug delivery system for cardiovascular disease. Int Heart J. 2014; 55(4):281-6. DOI: 10.1536/ihj.14-150. View

Humbert M, Lau E, Montani D, Jais X, Sitbon O, Simonneau G . Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2015; 130(24):2189-208. DOI: 10.1161/CIRCULATIONAHA.114.006974. View

10.

Hoeper M, Olschewski H, Ghofrani H, Wilkens H, Winkler J, Borst M . A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol. 2000; 35(1):176-82. DOI: 10.1016/s0735-1097(99)00494-5. View

11.

Hoeper M, Schwarze M, Ehlerding S, Spiekerkoetter E, Niedermeyer J, Hamm M . Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000; 342(25):1866-70. DOI: 10.1056/NEJM200006223422503. View

12.

Clapp L, Finney P, Turcato S, Tran S, Rubin L, Tinker A . Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002; 26(2):194-201. DOI: 10.1165/ajrcmb.26.2.4695. View

13.

Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin L . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347(5):322-9. DOI: 10.1056/NEJMoa020204. View

14.

Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P . Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40(4):780-8. DOI: 10.1016/s0735-1097(02)02012-0. View

15.

McLaughlin V, Shillington A, Rich S . Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106(12):1477-82. DOI: 10.1161/01.cir.0000029100.82385.58. View

16.

Barst R, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L . Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 41(12):2119-25. DOI: 10.1016/s0735-1097(03)00463-7. View

17.

Moncada S, Gryglewski R, Bunting S, Vane J . An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976; 263(5579):663-5. DOI: 10.1038/263663a0. View

18.

Starling M, NEUTZE J, Elliott R . Control of elevated pulmonary vascular resistance in neonatal swine with prostacyclin (PGI2). Prostaglandins Med. 1979; 3(2):105-17. DOI: 10.1016/0161-4630(79)90078-8. View

19.

Davies S, McKenna F, Turney J, WRIGHT V . Severe hypotension due to epoprostenol. Lancet. 1984; 2(8416):1401-2. DOI: 10.1016/s0140-6736(84)92095-6. View

20.

Rubin L, Mendoza J, Hood M, Mcgoon M, Barst R, Williams W . Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990; 112(7):485-91. DOI: 10.7326/0003-4819-112-7-485. View